A substantially solvent-free matrix layer containing ()-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.

The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.

A medical dressing comprising an absorbent adhesive layer having a pharmaceutically active agent incorporated, the non-skin-facing surface being provided with a backing layer and the skin facing surface being interrupted by a pattern of cavities. The cavities provide a storage room and distribution centre for wound exudates enabling the dressing to be applied to fast exuding wounds and at the same time allows for an increased initial release of the pharmaceutically active agent.

A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.

The present technology relates generally to devices for acne treatment, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and an active agent, wherein the amount of the active agent does not reduce the absorption properties of the hydrocolloid dressing. In exemplary embodiments, the active agent is salicylic acid, benzoyl peroxide or sulfur.

A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having an influenza virus infection and at least one complication risk factor. Generally, the amount is effective such that a reduction in a time to improvement of at least one symptom of an influenza virus infection is statistically significant as compared to that of a non-treated subject.

A transdermal formulation which can be applied to the skin, body, face using a combination of glutathione, in the presence of a wide range of active components while increasing permeation of active antioxidant agents. A therapeutically effective amount creates in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

A protective film for application to a portion of an individual's body having a top surface and a bottom surface opposite the top surface. An adhesive is disposed on the top surface for securing the protective film to a portion of an individual's body. An active ingredient is disposed on the top surface and mixed with the adhesive and configured to be disposed onto the portion of the individual's body where the protective film is applied. The protective film has a heel patch portion that generally has a U-shape for surrounding a heel of the individual. According to yet another aspect of the disclosure, the active ingredient includes a solution of water and glycerin with the following ingredients contained therein: mandelic acid at 10-20% in weight, salicylic acid at 2% in weight and bromelain at 10-25% in weight.

The present invention relates to an abuse deterrent transdermal patch, particularly transdermal patch for the transdermal administration of oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.

A therapeutic method of alleviating the symptoms of failed back surgery syndrome, post laminectomy syndrome, post-surgery syndrome, sympathetic dystrophies, macular degenerations, complex regional pain syndrome, reflex sympathetic dystrophy and neuropathies by administering to the afflicted subject a therapeutically effective amount of cetyl myristoleate alone, or in combination with selective effective amount of aspirin, gabapentin, pregabalin, duloxetine, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, neuroceuticals, Neurontin, Cymbalta, Lyrica, muscle relaxers, anti-depressants, nortriptyline, local anesthetics, and steroids.